22 results about "Lysophosphatidic acid" patented technology

The invention belongs to the field of biosynthesis, and in particular relates to LBD (Levandanenediol Pyrophosphate) synthase and engineered yeast for producing sclareol. In order to solve the problem that in the prior art, the sclareol biosynthesis yield is generally low, LSLPPs mutant containing at least one mutation of D730L, D374L, N674L or G379M is obtained by performing mutation and optimization on LSLPPs pyrophosphate synthase, and the mutant is used for sclareol synthesis. Meanwhile, in order to solve the problem of genetic instability caused by free plasmid expression of part of saccharomyces cerevisiae strains, a sclareol synthesis pathway is constructed in a yeast genome, and meanwhile, an acetyl coenzyme A synthesis pathway, an MVA pathway and a sclareol synthesis pathway are enhanced; chassis bacteria for synthesizing sclareol are modified in a manner of knocking out part of transcription inhibition factors, and the yield of a 5L fermentation tank reaches 26.11 g / L and is greatly improved compared with the prior art.

The present invention discloses a low - serum medium and its application in the preparation of cultured meat from Larimichthys crocea cells, which is also applicable to other marine or freshwater fish, belonging to the field of bioengineering technology. The low - serum medium comprises a basal medium, fetal bovine serum accounting for 30 - 80 μL / mL, and exogenous additives. The exogenous additives include human serum albumin, ascorbic acid, basic fibroblast growth factor polypeptide, human holo - transferrin, lysophosphatidic acid, and human recombinant IGF - 1. Based on the DMEM / F12 medium, the low - serum medium provided by the present invention adds six substances that promote cell growth, reduces the dependence of satellite cells on fetal bovine serum, effectively reduces the usage amount of fetal bovine serum, and saves the culture cost. Compared with the general - type medium (DMEM high - glucose, adding 10% FBS), the low - serum medium provided by the present invention has an equivalent effect on the maintenance and proliferation ability of cell stem cells.

The invention belongs to the technical field of medical diagnosis, and provides an HIV (human immunodeficiency virus) combined non-alcoholic fatty liver diagnosis and prediction marker and application. The marker comprises 39 biomarkers in total, wherein the 39 biomarkers comprise two intestinal microorganisms of enterobacter and klebsiella and 37 plasma metabolites of diacylglycerol, lysophosphatidic acid and the like; by integrating microbiome and metabonomics, the multi-dimensional marker is screened and verified, so that the problems of lack of high specificity and sensitivity, difficulty in early disease screening and incapability of effective risk assessment of an HIV (Human Immunodeficiency Virus) combined NAFLD (Non-Amplified Fragment Leukemia) early diagnosis method caused by unknown pathogenesis in the prior art are solved; the marker combination is applicable to preparation of diagnostic kits, construction of disease prediction models and development of targeted therapy drugs, and a theoretical basis is provided for early discovery, risk early warning and advanced intervention of the HIV combined with the non-alcoholic fatty liver disease.

The invention relates to the technical field of grease processing, and discloses a method for increasing the sn-2 DHA content in schizochytrium limacinum triglyceride. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is more than 120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to the sn-2 site of triglyceride is remarkably promoted, so that the yield and content of sn-2 DHA are improved.

No effective ameliorating / therapeutic agent has been provided for dementia, which is centered on Alzheimer-type dementia. The present invention addresses the problem of providing a novel ameliorating / treating agent for dementia by finding an agent capable of ameliorating / treating dementia. According to the present invention, provided is an ameliorating or therapeutic agent for dementia, which contains cyclic phosphatidic acid, carba-cyclic phosphatidic acid, thiacyclic phosphatidic acid, carba-lysophosphatidic acid or a salt thereof.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to a marker combination for risk assessment when an individual is exposed to electromagnetism and / or noise and application of the marker combination, and markers comprise one or more of 1-stearoyl-2-linoleoyl-sn-glycerin, 1-(9Z, 12Z-octadecadienoyl)-lysophosphatidic acid and N, N-dimethyl phosphatidyl ethanolamine (16: 0 / 16: 0). According to the present invention, the marker can significantly change in the early stage (less than or equal to 7 days) after the individual is exposed by electromagnetism and / or noise, and the abundance level of the marker in the blood sample from the individual is detected so as to rapidly achieve the early, accurate and non-invasive detection of the health risk when the individual is exposed by electromagnetism and / or noise, such that the application prospect is wide.

The present invention relates to a high-LPI lysolecithin and methods related to the same. The high-LPI product is produced through the reaction of lecithin with a unique method using solvent, buffer / water, and phospholipase. Using the current production method, LPI content increased from 1.4% to 3.2-13.1% using regular soy lecithin as the starting material and LPC, LPE and LPA contents also increased from 5.1%, 2.0%, 1.0% to 15.8%, 14.6% and 4.4% respectively.

The application provides a mycoplasma hyopneumoniae culture medium capable of significantly improving the strain titer and an application thereof, and belongs to the field of veterinary biological products. The mycoplasma hyopneumoniae culture medium is obtained by adding L-asparagine, myo-inositol, arachidonic acid, urea, histamine, sodium pyruvate, valproic acid, glyceric acid, lysophosphatidic acid, L-citrulline, L-glutamine and L-leucine into a KM2 culture medium containing Bama pig serum. The culture medium can significantly improve the growth rate and viable bacterial titer of the mycoplasma hyopneumoniae under a low serum concentration, and reduces the production cost.

The invention discloses a composition for enhancing cool feeling of a nasal cavity, application of the composition and atomized essence, and relates to the technical field of cooling agents. The composition for enhancing the cool feeling of the nasal cavity comprises a cooling agent, glucoside and an activating agent, wherein the activating agent comprises borneol and / or a phospholipid compound; wherein the glucoside comprises a hydrophilic group and a hydrophobic group; the phospholipid compound comprises at least one of lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine and phosphatidylinositol 4, 5 diphosphate. Glucoside is used for intercepting cooling agent molecules and increasing the exposure concentration of the cooling agent in the nasal cavity, so that the cool feeling strength of the nasal cavity is enhanced, borneol and / or phospholipid compounds are / is used as activating agents, the sensitivity of a cool feeling body is enhanced, and the cool feeling strength of the nasal cavity is further enhanced. The composition for enhancing the cool feeling of the nasal cavity can enhance the cool feeling of the nasal cavity in a targeted mode, and the problems that an existing cooling agent composition for atomized essence cannot target the nasal cavity, and the cool feeling intensity is low are solved.

To provide a compound which inhibits the physiological activity of lysophosphatidic acid (LPA) and is useful as a medicine for treating or preventing diseases for which the inhibition of the physiological activity of LPA is useful.SOLUTION: Provided are compounds having the structure of Formula 1 or a pharmaceutically acceptable salt or prodrug thereof.SELECTED DRAWING: None

The invention provides a method and a kit for diagnosing or identifying whether an individual suffers from liver cancer or not by detecting a metabolic biomarker, and the metabolic biomarker comprises 1-stearoyl-2-arachidonyl-sn-glycerol, NG, S-glycerol, S-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol, N-glycerol and N-glycerol. The compound is selected from one or more of N, N-dimethyl-L-arginine, N, N-dimethyl-L-arginine (ADMA), taurochenodeoxycholic acid, proline-valine (Pro-Val) and 1-oleoyl-L-alpha-lysophosphatidic acid.

The present invention belongs to the field of biotechnology and discloses the use of lysophosphatidic acid inhibitors in the preparation of drugs for inhibiting PRRSV replication. Through metabolomics analysis and screening, the present invention discovered that the natural metabolite lysophosphatidic acid (LPA) significantly promotes PRRSV replication. Targeted inhibition of LPA can effectively inhibit viral replication in infected pigs, alleviate clinical symptoms such as high fever and cough caused by porcine respiratory and reproductive syndrome (PRRS), significantly reduce viral loads in virus-infected tissues such as the lungs, spleen, and inguinal lymph nodes, and alleviate pathological damage to infected tissues. Therefore, lysophosphatidic acid inhibitors have great application prospects in the prevention and treatment of porcine reproductive and respiratory syndrome (PRRS).

The present invention addresses the problem of providing: a method that enables sufficient proliferation of cells, in particular immune competent cells, even in a serum-free medium or a low-serum medium; and a medium composition for use in this method. By incorporating imidazole dipeptide or a salt thereof, taurine or a precursor thereof, or a salt of these, and lysophosphatidic acid or a derivative thereof, a cell proliferation maintenance / promoting effect comparable to that of culture in a serum-containing medium can be obtained even in a serum-free medium or a low-serum medium.

The invention relates to the technical field of microbial oil processing, and discloses a method for increasing the content of phospholipid DHA in schizochytrium limacinum oil. The method comprises the following steps: adding a metabolic regulator into a fermentation culture solution containing schizochytrium limacinum, carrying out fermentation culture until the total fermentation time is 90-120 hours, and collecting a grease product, the metabolic regulator is selected from at least one of choline chloride, ethanolamine, inositol and lysophosphatidic acid. According to the method provided by the invention, the lipid metabolic flux of schizochytrium limacinum can be effectively regulated and controlled, and directional enrichment of DHA to phospholipid components is remarkably promoted, so that the yield and content of phospholipid DHA are improved.

The present application belongs to the field of biosynthesis, and particularly relates to pyrophosphate lyddane diol ester synthase and yeast engineering bacteria for producing sclareol. In order to solve the problem of generally low yield of sclareol biosynthesis in the prior art, the pyrophosphate lyddane diol ester synthase is mutated and optimized in the present application, and a SsLPPs mutant containing at least one mutation of D730L, D374L, N674L or G379M is obtained, and the mutant is used for sclareol synthesis. Meanwhile, in order to solve the problem of genetic instability existing in the expression of free plasmid in part of saccharomyces cerevisiae strains, the present application constructs a sclareol synthesis pathway in the yeast genome, and at the same time, the acetyl coenzyme A synthesis pathway, the MVA pathway and the sclareol synthesis pathway are strengthened, and part of the transcriptional repressor is knocked out, so that the bottom bacteria for synthesizing sclareol are modified. The yield in a 5 L fermenter reaches 26.11 g / L, and the yield is greatly improved compared with the prior art.

The purpose of the present invention is to provide a culture medium for culturing having excellent proliferation of mesenchymal stem cells. The present invention is a mesenchymal stem cell proliferation promoter containing 16: 0 lysophosphatidic acid, a derivative of 16: 0 lysophosphatidic acid, and / or a salt of the 16: 0 lysophosphatidic acid and / or the derivative of 16: 0 lysophosphatidic acid. It is preferable that the mesenchymal stem cell proliferation promoter additionally contains 18: 1 lysophosphatidic acid, a derivative of 18: 1 lysophosphatidic acid, and / or a salt of the 18: 1 lysophosphatidic acid and / or the derivative of 18: 1 lysophosphatidic acid. The present invention also includes a culture medium for mesenchymal stem cells containing 16: 0 lysophosphatidic acid, a derivative of 16: 0 lysophosphatidic acid, and / or salts of the 16: 0 lysophosphatidic acid and the derivative of 16: 0 lysophosphatidic acid.

According to the present invention, it is possible to develop a technique whereby lysophosphatidylcholine and lysophosphatidic acid in a cerebrospinal fluid can be analyzed with high accuracy by an analysis method comprising a step for detecting lysophosphatidylcholine and / or lysophosphatidic acid in a biological sample by mass spectrometry, and a lysophosphatidylcholine compound of which the choline part contains stable isotopes is used as a standard sample.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.

To provide a defensin expression promoter having an excellent defensin expression promoting action on the skin or in vivo.SOLUTION: Lysophosphatidic acid or its salt is used as an active ingredient. Since lysophosphatidic acid or a salt thereof has an excellent defensin expression promoting action on the skin or in vivo, it can be preferably used for the purpose of improving the antibacterial action on the skin or in vivo. It is particularly effective for promoting the expression of human β - defensin-1 and human β - defensin-3 among defensins. In addition, since lysophosphatidic acid or a salt thereof also has an action of suppressing proliferation of Propionibacterium acnes based on the action of promoting expression of human β - defensin-3, it can be used as an agent for suppressing proliferation of Propionibacterium acnes.SELECTED DRAWING: None

The invention provides a characteristic phospholipid molecular biomarker in plasma, a screening method thereof and application of the characteristic phospholipid molecular biomarker in preparation of a kit for diagnosing pneumoconiosis. The characteristic phospholipid molecules at least comprise the following nine phospholipid molecules: lysophosphatidylcholine (12: 0), phosphatidylcholine (16: 0 / 16: 0), phosphatidylcholine (18: 0 / 18: 1), phosphoinositide (16: 0 / 18: 1), lysophosphatidic acid (16: 0), phosphatidyl glycerol (16: 0 / 16: 0), phosphatidylserine (18: 1 / 18: 1), phosphatidylcholine (18: 0 / 20: 2) and lysophosphatidyl ethanolamine (18: 2). The TC value is calculated by calculating the quantitative values of the nine characteristic phospholipid molecules and a classification model constructed based on a support vector machine algorithm, the risk of pneumoconiosis is predicted according to the TC value, pneumoconiosis patients and non-pneumoconiosis patient groups can be accurately distinguished, and the method is used for pneumoconiosis diagnosis and early screening.

The present disclosure relates to compositions and methods for generating organoids having apical-out polarity or apical-in polarity. In particular, the disclosure provides methods for controlling the polarity (i.e. apical-out or apical-in) of organoids through culturing a population of cells (e.g., patient derived organoids) (e.g., undifferentiated organoid tissue) (e.g., pluripotent stem cell (PSC) derived organoids). To direct apical-out organoids, the disclosure provides methods where an organoid medium is used comprising one or both of lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). To direct apical-in organoids, the disclosure provides methods through culturing a population of cells (e.g., patient derived organoids) (e.g., undifferentiated organoid tissue) (e.g., PSC derived organoids) with an organoid medium lacking LPA and S1P.

Rice bran lyso-gums is a new class of by-product obtained during degumming of crude rice bran oil using bio-catalyst. Presently, this particular by-product is having very limited applications and is fetching negligible value to the industry. On the other hand, it contains lyso -phospholipids which has known applications in food, surfactant, pharmaceutical and cosmetics industries. The present invention relates to processes for possible value addition to crude rice bran lyso-gums- an unexplored by-product of rice bran oil refinery. It describes efficient processes for possible upgradation, modification, enrichment and purification of crude rice bran lyso-gums to obtain lyso-PC enriched rice bran lyso-lecithin having lighter colour by using various unit operation like drying, bleaching, solvent fractionation and chromatographic separation techniques in sequential manner.